A Phase III, Randomized, Open Label Trial of Nivolumab in Combination With Ipilimumab Versus Pemetrexed With Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma

Trial Profile

A Phase III, Randomized, Open Label Trial of Nivolumab in Combination With Ipilimumab Versus Pemetrexed With Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma

Recruiting
Phase of Trial: Phase III

Latest Information Update: 17 Aug 2017

At a glance

  • Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Carboplatin; Cisplatin; Pemetrexed
  • Indications Mesothelioma
  • Focus Registrational; Therapeutic Use
  • Acronyms CheckMate743
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 06 Jun 2017 Trial design of the study presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
    • 14 Nov 2016 Planned End Date changed from 1 Aug 2021 to 1 Sep 2021.
    • 14 Nov 2016 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top